Lisata Therapeutics to Present at the 2025 BIO International Convention

Core Insights - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [1][3] - The company will present a corporate overview at the 2025 BIO International Convention in Boston, scheduled for June 17, 2025 [1][2] Company Overview - Lisata's lead product candidate, certepetide, is designed to activate a novel uptake pathway for more effective targeting and penetration of solid tumors by anti-cancer drugs [3] - The company has established significant commercial and R&D partnerships based on its CendR Platform technology [3] - Lisata anticipates announcing multiple milestones over the next 1.5 years and expects its capital to fund operations into Q3 2026, covering anticipated data milestones from ongoing and planned clinical trials [3]